The prevalence of Neurological diseases is rising, and available treatments for many of these conditions are either minimally effective or nonexistent. Neurological diseases are one of the primary therapeutic areas where we have chosen to focus our efforts.
Read moreJulius Clinical’s focused approach has created a track record of excellence that testifies to our cardio-metabolic and kidney disease trial capabilities. We have honed our scientific site networks, collaborations with leading experts, and operational resources to deliver steady streams of patients and high-quality data for clients.
Read moreUnrecognised pathogens and reemerging infectious diseases are an ongoing threat to human health in every corner of the world. We contribute to important research in this area by conducting pioneering infectious disease and vaccine trials, doing what we do best: optimizing protocols and executing streamlined trials that deliver high-quality data.
Read moreThe prevalence of Neurological diseases is rising, and available treatments for many of these conditions are either minimally effective or nonexistent. Neurological diseases are one of the primary therapeutic areas where we have chosen to focus our efforts.
Read moreJulius Clinical’s focused approach has created a track record of excellence that testifies to our cardio-metabolic and kidney disease trial capabilities. We have honed our scientific site networks, collaborations with leading experts, and operational resources to deliver steady streams of patients and high-quality data for clients.
Read moreUnrecognised pathogens and reemerging infectious diseases are an ongoing threat to human health in every corner of the world. We contribute to important research in this area by conducting pioneering infectious disease and vaccine trials, doing what we do best: optimizing protocols and executing streamlined trials that deliver high-quality data.
Read more
Alzheimer's Disease CRO Expertise for Complex Clinical Trials As Alzheimer's research shifts toward earlier intervention and biomarker-defined populations, sponsors need more than operational support. They need a partner who understands the scien...
Ensuring that Alzheimer’s disease (AD) clinical trials reflect real-world patient populations remains a key challenge, as eligibility criteria can unintentionally influence who is able to participate. A recent study published in The Journal of P...
Metabolic dysfunction associated steatotic liver disease, or MASLD, is one of the fastest growing chronic liver conditions worldwide, yet advanced fibrosis frequently remains undiagnosed until later stages. A recent multicenter study published in ...
"*" indicates required fields
"*" indicates required fields
